Merck and Eisai announced new investigational data demonstrating positive top-line results from the Phase III KEYNOTE-581/CLEAR trial (Study 307).
ESMO News: AstraZeneca, Merck, Janssen, Amgen and More
Basal Cell Carcinoma, Blockbusters, Breast Cancer, Checkpoint Inhibitors, Clinical Data, Clinical Trial Endpoints, Clinical Trials, EGFR tyrosine kinase inhibitors (TKI), European Society for Medical Oncology (ESMO), Interim Data, MD Anderson Cancer Center, Melanoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic non-small cell lung cancer, Non-Small Cell Lung Cancer (NSCLC), Overall Survival (OS), R&D, Renal Cell Carcinoma (RCC), Therapeutics, TumorsNumerous companies presented clinical trial data and updates at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
Bristol Myers’ Opdivo with Exelixis drug cuts kidney cancer death risk: study
Analysts, Blockbusters, Clinical Data, Clinical Trials, Combination Therapies, European Society for Medical Oncology (ESMO), Immunotherapies, Kidney Cancer, Progression-Free Survival (PFS), R&D, Renal Cell Carcinoma (RCC), Researchers, TherapeuticsBristol Myers’ Opdivo with Exelixis drug cuts kidney cancer death risk: study NEW YORK (Reuters) – Bristol Myers Squibb Co’s cancer immunotherapy Opdivo in combination with Exelixis Inc’s Cabometyx reduced […]
Foghorn Therapeutics entered into a strategic collaboration with Merck to leverage Foghorn’s Gene Traffic Control platform for cancer therapies.
Bristol-Myers Squibb and Exelixis are eying potential approval of a combination therapy for renal cell carcinoma following results from a late-stage study that showed a combination of Opdivo and Cabometyx met the primary endpoint of progression-free survival.
AVEO Oncology Announces Submission of New Drug Application to U.S. FDA for Tivozanib in Patients with Relapsed or Refractory Renal Cell Carcinoma
FDA, FDA/Regulatory, Immunotherapy, New Drug Application Submission, Renal Cell Carcinoma (RCC), Tyrosine kinase inhibitors, Vascular Endothelial Growth Factor (VEGF) InhibitorsAVEO Oncology submitted a New Drug Application to the U.S. Food and Drug Administration for tivozanib, the company’s vascular endothelial growth factor receptor tyrosine kinase inhibitor, as a treatment for relapsed or refractory renal cell carcinoma (RCC).
A Phase III trial is planned after promising results were revealed from Dana-Farber Cancer Institute for MK-6482 in advanced clear cell kidney cancer.
Eli Lilly and Co.’s experimental pancreatic cancer treatment in combination with chemotherapy drugs failed to meet the main goal of overall survival in a late-stage study.
Top 200 Medicines Annual Report 2019: The king of medicines
Ankylosing Spondylitits, August 2019, Autoimmune Diseases, Biologics, Biosimilars, Blockbusters, Cervical Cancer, Classical Hodgkin Lymphoma, Crohn's Disease, Esophageal Cancer, Forecasts, Gastric Cancer, Head & Neck Cancer, Hepatocellular Carcinoma, Hidradenitis suppurativa, Issue Archives, Juvenile Idiopathic Arthritis, Market exclusivity, Melanoma, Merkel cell carcinoma, Metastatic Urothelial Carcinoma (mUC), Microsatellite instability-high (MSI-H) cancer, Monoclonal Antibodies, Non-Small Cell Lung Cancer (NSCLC), Plaque Psoriasis, Primary lediastinal large B-cell lymphoma, Product Launches, Psoriatic Arthritis, Renal Cell Carcinoma (RCC), Rheumatoid Arthritis, Therapeutics, Top 200 Medicines, Ulcerative Colitis, UveitisHumira’s dominance continues as the world’s top-selling prescription product as the biologic therapy is the first drug to exceed $20 billion in annual global sales.
June 2019 is a busy month for approval applications for the U.S. Food and Drug Administration as the regulatory agency has a slate of PDUFA dates.